Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 906-627-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
In an acute toxicity study with a mixture of cyclohexanol and cyclohexanone (not further specified) performed similar to the requirements of the OECD guideline study 401 the LD50 was determined with 1120 mg/kg (Monsanto, 1981).
In an acute inhalation hazard test performed with the mixture of cyclohexanol and cyclohexanone (similar to the requirements of the OECD guideline 403) the LC50 was found to be > 6.6 mg/l.
No data on dermal acute toxicity are available.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- yes
- Remarks:
- no data on substance purity, prior to GLP, limited reporting on study design and methods
- GLP compliance:
- no
- Test type:
- standard acute method
- Specific details on test material used for the study:
- Composition: no data
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Route of administration:
- oral: unspecified
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- - MAXIMUM DOSE VOLUME APPLIED: not reported
- Doses:
- 794, 1000, 1260, 1580 mg/kg bw
- No. of animals per sex per dose:
- 5 animals/sex/dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: no data
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 1 120 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 030 - 1 220
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 1 120 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 970 - 1 290
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 1 120 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 010 - 1 250
- Mortality:
- 794 mg/kg bw: males 0/5; females 0/5
1000 mg/kg bw: males 2/5; females 1/5
1260 mg/kg bw: males 3/5; females 4/5
1580 mg/kg bw : males 5/5; females 5/5
All deaths occured within 2 days - Clinical signs:
- other: Lethargy (lastuing up to 7 days), increasing weakness, ocular discharge, collapse and death
- Gross pathology:
- Decedents: Hemorrhagic lungs, liver hyperemia, discoloration of liver, kidneys and spleen, and acute gastrointestinal infolammation;
Survivors: Viscera appeard normal
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 120 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Version / remarks:
- (Inhalation hazard test)
- Deviations:
- yes
- Remarks:
- (only 6 hours of exposure, only 6 animals of one sex)
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 260 g
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22
- Humidity (%): 70 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- not specified
- Vehicle:
- other: unchanged (no vehicle)
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure chamber volume: 35 l - Duration of exposure:
- 6 h
- Concentrations:
- 6.6 mg/l
- No. of animals per sex per dose:
- 6 males
- Control animals:
- no
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- > 6.6 mg/L air
- Exp. duration:
- 6 h
- Remarks on result:
- other: no mortality occurred
- Mortality:
- No animals died
- Clinical signs:
- other: No toxic signs
- Body weight:
- Day 7: 330 g
Day 14: 390 g - Gross pathology:
- Viscera appeared normal
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating conc.
- Value:
- 6 600 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Cyclohexanol:
In four acute toxicity studies (comparable to OECD guideline 401) the LD50 ranged from 1400 - 2060 mg/kg bw. In two reliable acute inhalative studies the LC50 was shown to be >3.6 mg/l (saturated atmosphere, 4 hours) and > 5.92 mg/l (saturated atmosphere, 7h). In a third study the LC50 was determined to be >4.3 mg/l.
All these studies suggest that cyclohexanol is of moderate acute toxicity via the oral and inhalative route of exposure.
Regarding the dermal acute toxicity no reliable studies are available for an assessment.
Cyclohexanone:
The approx. LD50 for acute oral toxicity in the rat is between 1890 (test with 2 - 50% aqueous emulsion with traganth) and 2650 mg/kg (test with solution in olive oil). Clinical signs were prone and lateral position and narcosis. Pathology showed no abnormal findings. This test was carried out according to BASF-internal standards (testing date: 1966; no data about sex of the animals are available).
Smyth et al. (1969) found an acute oral LD50 value of 1620 mg/kg for male rats (gastric intubation). No data are given for mortalities in single dose groups, clinical signs or gross pathology. All other data/studies available for this route of exposure showed LD50 values near or below 2000 mg/kg.
An LC50 value of > 6.2 mg/l/4 hours for both sexes (rat) was found in an acute inhalation study (BASF-internal standards). No mortalities were seen. Clinical signs were watery eye and nose secretion, mouth smearing, intermittent and accelerated breathing, apathetic, narcosis, scrubby fur. Theses symptoms were seen until day of sacrifice. These data would not indicate a classification for this exposure route.
No available data have been obtained for the dermal exposure route according to present testing guidelines (semiocclusive; 4 hrs exposure time). From the chemical structure and the physical-chemical properties, however, a ready dermal absorption and, hence, a toxicity of similar order of magnitude as from oral administration can be assumed. There is also evidence, that humans metabolize Cyclohexanone in partially different pathways as rats. It appears therefore to be prudent to classify Cyclohexanon also for the dermal exposure route.
Reaction mass of cyclohexanol and cyclohexanone:
In an acute toxicity study with a mixture of cyclohexanol and cyclohexanone (not further specified) performed similar to the requirements of the OECD guideline study 401 the LD50 was determined with 1120 mg/kg (Monsanto, 1981). In an acute inhalation hazard test performed with the mixture of cyclohexanol and cyclohexanone (similar to the requirements of the OECD guideline 403) the LC50 was found to be > 6.6 mg/l. No data on dermal acute toxicity are available.
Justification for classification or non-classification
Cyclohexanol:
Regarding acute oral toxicity the substance is classified with Cat. 4 according to Annex VI of Regulation (EC) No. 1272/2008.
The available relevant data on acute oral toxicity support the legal classification.
For acute inhalative toxicity, cyclohexanol is classified with Cat. 4 according to Annex VI of Regulation (EC) No. 1272/2008.
From the chemical structure and the physical-chemical properties, a ready dermal absorption and, hence, a toxicity of similar order of magnitude as from oral administration can be assumed. Therefore, the substance has also been classified for acute dermal toxicity (Cat.4, H312).
Cyclohexanone:
The test substance is classifed for acute inhalation toxicity with Cat. 4 (H 332) according to Annex VI of Regulation (EC) No. 1272/2008.
Based on the data available, the substance has been classified for acute oral toxicity (Cat.4, H302) according to Regulation (EC) No. 1272/2008
From the chemical structure and the physical-chemical properties, a ready dermal absorption and, hence, a toxicity of similar order of magnitude as from oral administration can be assumed.
Therefore, the substance has also been classified for acute dermal toxicity (Cat.4, H312).
Reaction mass of Cyclohexanol and Cyclohexanone:
Based on the data avaiable, the reaction mass is classified for acute toxicity with Cat.4 for all three routes of exposure (H302, H312, H332).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
